Biofrontera (BFRI) Q4 2025 Earnings Transcript
View original at finance.yahoo.comBiofrontera (BFRI) Q4 2025 Earnings Transcript Image source: The Motley Fool. DATE Thursday, March 19, 2026 at 10 a.m…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
During 2025, approximately 85 RhodoLED lamps were placed within dermatology practices, including approximately 70 of the newer XL model
60% confidenceQ4 2025 revenues were approximately $17.1 million compared with $12.6 million in 2024, an increase of approximately 36%
60% confidenceFull year 2025 increase in revenue was primarily driven by $4.1 million in organic Ameluz growth associated with volume
60% confidenceGross profit on sales improved from about 58% to 82% in Q4 2025
60% confidenceIf approved, Ameluz would be the first PDT drug to treat a tumor in the United States
60% confidenceAmeluz unit volumes for full-year 2025 increased meaningfully with Q4 at approximately 49,840 tubes, bringing full-year volume to approximately 121,000 tubes, representing approximately 10% volume growth over 2024
60% confidenceTotal operating expenses for Q4 were $12.5 million compared with $14.3 million in 2024
60% confidenceFull year 2025 related-party COGS decreased by $7.7 million, or 43%, to $10.1 million from $17.9 million in 2024
60% confidenceRelated-party cost of goods sold decreased 45% year over year in Q4, driven by transition from transfer pricing model to lower earn-out structure
60% confidenceFull year 2025 R&D expense increased $1.6 million to $3.7 million, reflecting responsibility for all U.S. clinical trials
60% confidenceQ4 2025 adjusted EBITDA margin improved to positive 29% from negative 11% in prior year
60% confidenceFull year 2025 net loss was $10.5 million, improvement from net loss of $17.8 million in 2024, reduction of approximately 41%
60% confidenceQ4 2025 net income was $5.6 million, a $7.0 million improvement from net loss of $1.4 million in Q4 2024
60% confidenceIn the long run, expect gross profit margin to range between 80% and 85%
60% confidenceFull year 2025 SG&A increased $4.0 million, or approximately 12%, to $38.4 million, driven by $6.0 million increase in legal expenses
60% confidencePlan to discuss design of future Phase III program with FDA in 2026 for acne vulgaris indication
60% confidenceCompany opened over 150 new accounts in 2025 and gained significant volume through these new accounts
60% confidenceFDA has PDUFA target action date of September 28, 2026 for sBCC supplemental NDA
60% confidencePlanning for full rollout of inside sales in 2026 based on success of Q4 2025 pilot
60% confidenceQ4 2025 operating income was $4.6 million, a $6.3 million improvement from net loss of $1.7 million in Q4 2024
60% confidenceFull year 2025 operating loss was $11.3 million, a significant improvement from net loss of $17.2 million in 2024, a reduction of approximately 34%
60% confidence$2.0 million of purchase price accruals under prior agreement were forgiven in connection with the closing
60% confidenceNew royalty structure is 12% when annual U.S. Ameluz net sales are at or below $65 million and 15% when they exceed that threshold, replacing transfer pricing model of 25% to 35% of revenue
60% confidenceBiofrontera Inc. is the only company in the United States running FDA-controlled clinical studies in PDT for dermatology
60% confidenceApproximately 58 million American adults have at least one actinic keratosis lesion
60% confidenceCost of revenues per unit declined steadily to about 15% compared with range of 25% to 35% under prior agreement
60% confidencePatent protection for Ameluz extends through 2043
60% confidenceNew 12% cost rate applied only to about 45% of Ameluz sales volume in 2025
60% confidenceThree-hour incubation protocol demonstrated 58% reduction in inflammatory lesions with Ameluz compared to 37% with vehicle gel in Phase II acne study
60% confidence86% of PDT patients stated they would choose PDT treatment again in acne study
60% confidence